Transient dephosphorylation of p53 serine 376 as an early response to ionizing radiation

Radiation Research

Volumn 171, Issue 6, 2009, Pages 725-734

  Warters, Raymond L ^a   Gaffney, David K ^a   Kramer, Gwen F ^a   Martinez, Jesse D ^b   Cress, Anne E ^b  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALYCULIN A; CYCLOHEXIMIDE; EPITOPE; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN P53; SERINE; AUTOANTIBODY; CESIUM; ENZYME INHIBITOR; OXAZOLE DERIVATIVE; PROTEIN SYNTHESIS INHIBITOR;

ARTICLE; CANCER CELL CULTURE; CELL FATE; CELL NUCLEUS; CONTROLLED STUDY; DNA DAMAGE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IONIZING RADIATION; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; RADIATION EXPOSURE; RADIATION RESPONSE; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; AMINO ACID SEQUENCE; CYTOPLASM; DRUG EFFECT; FLUORESCENCE MICROSCOPY; GAMMA RADIATION; GENETICS; METABOLISM; PHOSPHORYLATION; TIME; TUMOR CELL LINE; WESTERN BLOTTING;

AMINO ACID SEQUENCE; AUTOANTIBODIES; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL NUCLEUS; CESIUM RADIOISOTOPES; CYCLOHEXIMIDE; CYTOPLASM; DOSE-RESPONSE RELATIONSHIP, RADIATION; ENZYME INHIBITORS; GAMMA RAYS; HUMANS; MICROSCOPY, FLUORESCENCE; OXAZOLES; PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITORS; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67849083188     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR1576.1     Document Type: Article

References (58)

1. A. J. Levine, p53, the cellular gatekeeper for growth and division. Cell 88, 323-331 (1997).
2. A. J. Giaccia and M. B. Kastan, The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 12, 2973-2983 (1998).
3. M. F. Lavin and N. Gueven, The complexity of p53 stabilization and activation. Cell Death Differ. 13, 941-950 (2006).
4. M. B. Kastan, Q. Zhan, W. S. el-Deiry, F. Carrier, T. Jacks, W. V. Walsh, B. S. Plunkett, B. Vogelstein and A. J. Fornace, A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia- telangiectasia. Cell 71, 587-597 (1992).
5. M. C. Hollander, I. Alamo, J. Jackman, O. W. McBride and A. J. Fornace, Analysis of the mammalian gadd45 gene and its response to DNA damage. J. Biol. Chem. 268, 24385-24393 (1993).
6. W. S. El-Deiry, T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler and B. Vogelstein, WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825 (1993).
7. M. B. Kastan, O. Onyekwere, D. Sidransky, B. Vogelstein and R. W. Craig, Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51, 6304-6311 (1991).
8. X. Lu and D. P. Lane, Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell 75, 765-778 (1993)
9. B. D. Price and S. K. Calderwood, Increased sequence-specific p53-DNA binding activity after DNA damage is attenuated by phorbol esters. Oncogene 8, 3055-3062 (1993).
10. M. B. Kastan, O. Onyekwere, D. Sidransky, B. Vogelstein and R. W. Craig, Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51, 6304-6311 (1991).
11. W. Maltzman and L. Czyzyk, UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol. 4, 1689-1694 (1984).
12. W. G. Nelson and M. B. Kastan, DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol. 14, 1815-1823 (1994).
13. 1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol. Cell. Biol. 14, 6264-6277 (1994).
14. J. M. Nigro, K. D. Aldape, S. M. Hess and T. D. Tlsty, Cellular adhesion regulates p53 protein levels in primary human keratinocytes. Cancer Res. 57, 3635-3639 (1997).
15. 1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev. 10, 934-947 (1996).
16. P. Hainaut and J. Milner, Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res. 53, 4469-4473 (1993).
17. L. C. Huang, K. C. Clarkin and G. M. Wahl, Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1 arrest. Proc. Natl. Acad. Sci. USA 93, 4827-4832 (1996).
18. G. M. Wahl, S. P. Linke, T. G. Paulson and L. C. Huang, Maintaining genetic stability through TP53 mediated checkpoint control. Cancer Surv. 29, 183-219 (1997).
19. T. R. Hupp, D. W. Meek, C. A. Midgley and D. P. Lane, Regulation of the specific DNA binding function of p53. Cell 71, 875-886 (1992).
20. Y. Wang and W. Eckhart, Phosphorylation sites in the amino-terminal region of mouse p53. Proc. Natl. Acad. Sci. USA 89, 4231-4235 (1992).
21. S. Y. Shieh, M. Ikeda, Y. Taya and C. Prives, DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91, 325-334 (1997).
22. J. D. Siliciano, C. E. Canman, Y. Taya, K. Sakaguchi, E. Appella and M. B. Kastan, DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev. 11, 3471-3481 (1997).
23. S. Y. Shieh, Y. Taya and C. Prives, DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization. EMBO J. 18, 1815-1823 (1999).
24. T. Unger, T. Juven-Gershon, E. Moallem, M. Berger, R. Vogt Sionov, G. Lozano, M. Oren and Y. Haupt, Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J. 18, 1805-1814 (1999).
25. A. Hirao, Y. Kong, S. Matsuoka, A. Wakeman, J. Ruland, H. Yoshida, D. Liu, S. J. Elledge and T. W. Mak, DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 287, 1824-1827 (2000).
26. R. Honda, H. Tanaka and H. Yasuda, Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420, 25-27 (1997).
27. Y. Haupt, R. Maya, A. Kazaz and M. Oren, Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299 (1997).
28. M. H. G. Kubbutat, S. N. Jones and K. H. Vousden, Regulation of p53 stability by Mdm2. Nature 387, 299-303 (1997).
29. D. E. Fisher, Apoptosis in cancer therapy: crossing the threshold. Cell 78, 539-542 (1994).
30. 1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc. Natl. Acad. Sci. USA 92, 8493-8497 (1995).
31. M. Hollstein, D. Sidransky, B. Vogelstein and C. C. Harris, p53 mutations in human cancers. Science 253, 49-53 (1991)
32. A. J. Lavine, J. Momand and C. A. Finlay, The p53 tumour suppressor gene. Nature 351, 453-456 (1991).
33. U. M. Moll, G. Riou and A. J. Levine, Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc. Natl. Acad. Sci. USA 89, 7262-7266 (1992).
34. K. Vogan, M. Bernstein, J. M. Lecler, L. Brisson, J. Brossard, G. M. Brodeur, J. Pelletier and P. Gros, Absence of p53 gene mutations in primary neuroblastomas. Cancer Res. 53, 5269-5373 (1993).
35. H. Komuro, Y. Hayashi, M. Kawamura, K. Hayashi, Y. Kaneko, S. Kamoshita, R. Hanada, K. Yamamoto, T. Hongo and M. Yamada, Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas. Cancer Res. 53, 4053-4288 (1993).
36. C. L. Schlamp, G. L. Poulsen, T. M. Norks and R. W. Nickells, Nuclear exclusion of wild-type p53 in immortalized human retinoblastoma cells. J. Natl. Cancer Inst. 89, 1530-1536 (1997).
37. S. C. Goldman, C. Y. Chen, T. J. Lansing, T. M. Gilmer and M. B. Kastan, The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization. Am. J. Pathol. 148, 1381-1385 (1996).
38. J. D. Martinez, M. E. Pennington, M. T. Craven, R. L. Warters and A. E. Cress, Free radicals generated by ionizing radiation signal nuclear translocation of p53. Cell Growth Differ. 8, 941-949 (1997).
39. R. Jasty, J. Lu, T. Irwin, S. Suchard, M. G. Clarke and V. P. Castle, Role of p53 in the regulation of irradiation-induced apoptosis in neuroblastoma cells. Mol. Genet. Metab. 65, 155-164 (1998).
40. F. Ronca, K. S. Y. Yee and V. C. Yu, Retinoic acid confers resistance to p53-dependent apoptosis in SH-SY5Y neuro-blastoma cells by modulating nuclear import of p53. J. Biol. Chem. 274, 18128-18134 (1999).
41. 1 checkpoint after DNA damage. Mol. Cell Biol. 16, 1126-1137 (1996).
42. 1 checkpoint function is attenuated. Clin. Cancer Res. 5, 4199-4207 (1999).
43. F. J. O'Neill, Y. Hu, T. Chen and H. Carney, Identification of p53 unbound to T-antigen in human cells transformed by simian virus 40 T-antigen. Oncogene 14, 955-965 (1997).
44. M. J. F. Waterman, E. S. Stavridi, L. F. Waterman and T. D. Halazonetis, ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nat. Genet. 19, 175-178 (1998).
45. N. Chandar, B. Billig, J. McMaster and J. Novak, Inactivation of p53 gene in human and murine osteosarcoma cells. Br. J. Cancer 65, 208-214 (1992).
46. H. Ishihara, B. L. Martin, D. L. Brautigan, H. Karaki, H. Ozaki, Y. Kato, N. Fusetani, S. Watabe, K. Hashimoto and D. J. Harshorne, Calyculin A and okadaic acid: inhibitors of protein phosphatase activity. Biochem. Biophys. Res. Commun. 159, 871-877 (1989).
47. I. Takenaka, F. Morin, B. R. Seizinger and N. Kley, Regulation of the sequence-specific DNA binding function of p53 by protein kinase C and protein phosphatases. J. Biol. Chem. 270, 5405-5411 (1995).
48. J. F. Ward, DNA damage produced by ionizing radiation in mammalian cells: identities, mechanisms of formation, and reparability. Prog. Nucleic Acid Res. Mol. Biol. 35, 95-125 (1988).
49. R. L. Warters and J. L. Roti Roti, Excision of X-ray-induced thymine damage in chromatin from heated cells. Radiat. Res. 79, 113-121 (1979).
50. J. F. Ward, E. I. Joner and W. F. Blakely, Effects of inhibitors of DNA strand break repair on HeLa cell radiosensitivity. Cancer Res. 44, 59-63 (1984).
51. A. E. Cress and G. T. Bowden, Covalent DNA-protein crosslinking occurs after hyperthermia and radiation. Radiat. Res. 95, 610-619 (1983).
52. M. Lobrich, M. Kuhne, J. Wetzel and K. Rothkamm, Joining of correct and incorrect DNA double-strand break ends in normal human and ataxia telangiectasia fibroblasts. Genes Chromosomes Cancer 27, 59-68 (2000).
53. M. N. Cornforth and J. S. Bedford, On the nature of a defect in cells from individuals with ataxia-telangiectasia. Science 227, 1589-1591 (1985).
54. M. Mundt, T. Hupp, M. Fritsche, C. Merkle, S. Hansen, D. Lane and B. Groner, Protein interactions at the carboxyl terminus of p53 result in the induction of its in vitro transactivation potential. Oncogene 15, 237-244 (1997).
55. T. R. Hupp, D. W. Meek, C. A. Midgley and D. P. Lane, Regulation of the specific DNA binding function of p53. Cell 71, 875-886 (1992).
56. K. Webley, J. A. Bond, C. J. Jones, J. P. Blaydes, A. Craig, T. Jupp and D. Wynford-Thomas, Posttranslational modifications of p53 in replicative senescence overlapping but distinct from those induced by DNA damage. Mol. Cell. Biol. 20, 2803-2808 (2000).
57. L. A. Kachnic, B. Wu, H. Wunsch, K. L. Mekeel, J. S. DeFrank, W. Tang and S. N. Powell, The ability of p53 to activate downstream genes p21 (WAF1/cip1) and MDM2, and cell cycle arrest following DNA damage is delayed and attenuated in scid cells deficient in the DNA-dependent protein kinase. J. Biol. Chem. 274, 13111-13117 (1999).
58. W. A. Price, C. C. Stobbe, S. J. Park and J. B. Chapman, Radiosensitization of tumour cells by cantharidin and some analogues. Int. J. Radiat. Biol. 80, 269-279 (2004).